share_log

Oppenheimer Maintains Outperform on Gain Therapeutics, Maintains $9 Price Target

Moomoo 24/7 ·  Apr 23 08:21

Oppenheimer analyst Hartaj Singh maintains Gain Therapeutics (NASDAQ:GANX) with a Outperform and maintains $9 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment